Market Currents
Lexicon Pharma (LXRX) +6.2% premarket after publishing results of two studies of its LX4211 oral...
-
Friday, June 29, 2012, 8:44 AM ETLexicon Pharma (LXRX) +6.2% premarket after publishing results of two studies of its LX4211 oral drug for type 2 diabetes in the journal Clinical Pharmacology & Therapeutics, adding to positive results released earlier this week.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
